Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;25(8):583-589.
doi: 10.1016/j.clml.2025.03.005. Epub 2025 Mar 13.

Advancing the Management of CH, MDS, and AML From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference

Hetty E Carraway  1 , Andrew M Brunner  2 , Catherine E Lai  3 , Marlise R Luskin  4 , Jae Park  5 , Alexander E Perl  3 , Eytan M Stein  6 , Eunice S Wang  7 , Amer M Zeidan  8 , Joshua F Zeidner  9 , Rami Komrokji  10
Affiliations

Advancing the Management of CH, MDS, and AML From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference

Hetty E Carraway et al. Clin Lymphoma Myeloma Leuk. 2025 Aug.

Abstract

Purpose: The management of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have evolved substantially in recent years with the development of targeted therapies and novel nontargeted approaches. However, many questions remain about how to best use current therapies, and there is a large unmet need for effective therapies, particularly for patients with higher-risk MDS, AML, and those with MDS/AML relapsed/refractory (R/R) to prior therapy.

Methods and results: A panel of experts was assembled to discuss current controversies and unanswered questions in the care of patients with MDS and AML. Workshop topics included: molecular testing and new classification systems, clonal hematopoiesis, treatment of MDS (lower-risk and higher-risk), frontline treatment of AML, treatment of special populations, treatment of R/R AML, and novel approaches.

Conclusions: We identified many areas of ongoing controversy in the diagnosis and management of MDS and AML related to classification and risk assessment, treatment selection, sequencing of therapies, and monitoring of responses. Many clinical trials are ongoing to further improve outcomes for patients with MDS and AML, and we noted potential areas of debate related to study design, selection of endpoints, and assessment of responses. The controversies and gaps in knowledge identified by this panel will inform a follow-up conference in 2025 that will employ a modified Delphi method with a goal of developing and publishing formal consensus recommendations that can provide actionable guidance to clinicians in practice.

Keywords: Clonal hematopoiesis; Higher-risk MDS; Lower-risk MDS; Molecular testing; Relapsed/refractory AML.

PubMed Disclaimer

Conflict of interest statement

Disclosure HEC reports serving for advosiry boards for Agios, Abbvie, Biomea, Jazz, Geron, Novartis, Stemline, Daiichi Sayko, Genentech, and BMS. She has had research funding for an investigator initiated clinical trial from Celgene. She has served on a DSMB for Syndax. AMB reports consulting for Agios, BMS, iMab Biopharma, Keros Therapeutics, Lava Therapeutics, Geron, Novartis, Rigel Pharmaceuticals, Takeda Oncology. CEL reports serving on advisory boards for Servier, Daiichi, and Abbvie; consulting for Abbvie, BMA, Genetech, Rigel, and Astellas; and research funding from BMS and Jazz Pharma. MRL reports serving on advisory roles for Pfizer, Novartis, Jazz, and KITE, and institutional research support from Novartis and AbbVie. EMS reports consulting fees from Abbvie, Agios, Astellas, AstraZeneca, Celgene, Genentech, Gilead, Jazz, Servier, Syndax, and Kura. ESW reports advisory/consulting for Abbvie, Blueprint, Daiichi Sankyo, Immunogen, Kite, Kura, Novartis, Qiagen, Rigel, Ryvu, Schrodinger, Servier, Stemline, Syndax, and Takeda; speaking for Pfizer, Astellas, and Dava; data safety monitoring committee for Gilead and Abbvie; and section editor for UptoDate. AMZ received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Cardiff Oncology, Incyte, Takeda, Novartis, Shattuck Labs, Geron, and Aprea; and participated in participated in advisory boards, consulted and/or received honoraria from AbbVie, Agios, Pfizer, Astellas, Astex, ALX Oncology, Amgen, Akeso pharma, BeiGene, BMS/Celgene, BoehringerIngelheim, BioCryst, Chiesi, Daiichi Sankyo, Epizyme, Faron, Geron, Gilead, Genentech, Glycomimetics, Hikma, Ionis, Janssen, Kura, Keros, Karyopharm, Kyowa Kirin, Lava Therapeutics, Mendus, Notable, Novartis, Otsuka, Orum, Taiho, Takeda, Treadwell, Syndax, Sumitomo, STCube, Schrodinger, Servier, Syros, Vincerx, Regeneron, Rigel, and Zentalis. JFZ reports consultancy and/or honoraria from advisory boards: AbbVie, Daiichi Sankyo, Foghorn, Gilead, Novartis, Sellas, Servier, Shattuck Labs, Sumitomo Dainippon, and Syndax; and research funding from AbbVie, Akeso Biopharma, Arog, Astex, Astra Zeneca, Gilead, Jazz, Loxo, Merck, Newave, Novartis, Sellas, Shattuck Labs, Stemline, Sumitomo Dainippon, and Zentalis.

MeSH terms